Heart ultrasound may reveal who gets the most from heart failure drug

NCT ID NCT07088471

Completed Knowledge-focused Sponsor: Connolly Hospital Blanchardstown Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 334 adults with heart failure and reduced pumping ability. Researchers used ultrasound to measure left atrial strain before and after starting sacubitril/valsartan, a drug known to improve survival. The goal was to see if these measurements could predict who responds best to the drug, potentially helping doctors tailor treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril/valsartan (a combination drug that helps the heart work better)
What this could lead to: If successful, this could help doctors predict which heart failure patients will benefit most from sacubitril/valsartan, leading to more personalized treatment.
What could go wrong: This is a completed observational analysis, not a new treatment trial. The findings may not change practice directly and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE AND REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE AND REDUCED EJECTION FRACTION

Contacts and locations

Locations

Connoly Hospital Blanchardstown

Dublin, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.